ARENSIA Exploratory Medicine GmbH

ARENSIA Exploratory Medicine GmbH is a German operator of professional research clinics, specializing in conducting early-phase patient trials. The company's slogan emphasizes its focus on early-phase clinical trials, including Phase IB, IIA, and PROOF OF CONCEPT studies with novel compounds, covering a wide range of patient populations. ARENSIA's clinics, strategically located within or adjacent to large university/private hospitals in various cities, prioritize patient safety and comfort, offering access to innovative therapies early in the drug development process. The company's dedicated research-oriented infrastructure enables an impressive time reduction of avg. 60% through outstanding recruiting performance compared to typical clinical trial sites. This is achieved by concentrating efforts in a few ARENSIA Clinics, reducing the overall budget for Phase IB/IIA PROOF OF CONCEPT trials by 50%. The 93% repeat business demonstrates ARENSIA’s disruptive breakthrough in time and cost, leading to continuous growth and collaborations with leading pharmaceutical companies worldwide, numerous biotechs, and global CROs. Founded in 2010 and operating in the biotechnology industry, ARENSIA's innovative approach to early-phase clinical trials positions it as a key player in accelerating drug development and improving patient access to breakthrough therapies.